Search results: (10000)
News Is long-term treatment with ixekizumab sufficiently safe?
Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A poster presented at last year's European Academy of Dermatology and Venereology (EADV) congress summarizes ixekizumab safety data from monitoring lasting up to 5 years, based on nearly 18,000 patient-years (PY) in the treatment of this disease.
News How to Maintain Hygiene for Incontinent Patients Without Using Water?
Urinary incontinence brings numerous health risks. Due to frequent continuous contact of aggressive urine with the skin, a significant number of patients develop skin complications such as eczema, rashes, or even pressure sores. Maximum care should therefore be devoted to the hygiene of intimate areas in all incontinent patients.
News Genetic Profiling Transforms the Diagnosis and Treatment of Cancer Diseases
Genome sequencing provides doctors with more information about the causes of cancer diseases and changes the ways of treating tumors. Targeted therapy aimed at oncogenic mutations has brought patients longer survival and better clinical outcomes. Let's take a closer look at the advances and challenges of using genomics in oncology.
News Does the emergence of resistance to cetuximab mean ineffectiveness of all anti-EGFR antibodies?
Colorectal cancer (CRC) cells respond to targeted therapy in different ways. Besides the desired outcome of cell death, CRC cells can adapt and survive through changes in their genome. It is important to recognize that the developed resistance to targeted therapy may, but does not necessarily, apply uniformly across a class of drugs or a single mechanism of action.
News VIDEO: Antibiotic Treatment of Infections Caused by MDR Bacteria – Seminar Recording
Recording of a professional seminar on the topic of infections caused by MDR bacteria, which took place on November 2, 2021, at the Medical House in Prague.
News Heart Failure in Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd at 5 PM.
You can find more information in the attached invitation below.
You can find more information in the attached invitation below.
News Heart Failure in the Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd, at 5 PM.
You can find more information in the invitation attached below.
You can find more information in the invitation attached below.
News Early Intervention in the Early Phase of Psychosis
A meta-analysis of 10 randomized studies examined whether early intervention in the initial phase of psychosis in patients with schizophrenia is associated with better outcomes than usual care.
News Association between Cardiovascular Risk Factors and Cognitive Disorders in Patients with Schizophrenia
Schizophrenia is a disease characterized by a certain degree of cognitive impairment, but also an increased risk of cardiovascular diseases, which are often the cause of deteriorating cognitive functions in the general population. The aim of a large meta-analysis was to elucidate the association between cardiovascular risk factors and cognitive disorders in patients with schizophrenia and schizoaffective disorder, based on the results of a previous smaller study that demonstrated an association between metabolic syndrome, diabetes, and cognitive disorders.
News Dust Mite Allergy and the Risk of Sleep-Disordered Breathing
New York authors in their recently published retrospective analysis tested the hypothesis that individuals with allergic rhinitis caused by dust mite allergy have an increased risk of breathing disorders during the REM phase of sleep, based on objective polysomnography evaluation.
News Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction
Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of death from cardiovascular causes or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetic and non-diabetic patients. The aim of the EMPEROR-Reduced clinical study was to supplement data on the effect of empagliflozin on the incidence of heart failure worsening events requiring hospitalization or outpatient treatment.
News Overlap of SGLT2 Inhibitors from Diabetology to Cardiology
As recent research shows, one of the modern groups of antidiabetic drugs - SGLT2 inhibitors, also known as gliflozins - brings benefits not only in diabetology but also in cardiology and nephrology. It has been confirmed that representatives of this class of drugs prolong patients' lives, reduce the incidence of major cardiovascular (CV) events and the risk of heart failure (HF), and improve renal function. A recently published study additionally indicates that the CV benefit of empagliflozin is independent of the number of compensated CV risk factors and manifests within the first 3 months of treatment.
News Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA
Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A is not always simple. An interesting perspective and recommendations are provided by a model analysis assessing the cost and effectiveness of individual available preparations.
News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).
News Screening using NGS in patients with metastatic NSCLC – initial results from the ALK-positive cohort
Next-generation sequencing (NGS) allows for obtaining a large amount of information about the tumor genome from a patient's blood sample. Currently, the method is recommended as an alternative in cases of insufficient tissue samples for standard biopsy examination. The first results of an ongoing prospective study provide insights into the role of NGS in mutation screening for patients with non-small cell lung cancer without a concurrent biopsy examination.